Prime Therapeutics to Present New Research at Academy of Managed Care Pharmacy Conference in April

ST. PAUL, Minn., March 31 /PRNewswire/ -- Prime Therapeutics LLC (Prime), a thought leader in pharmacy benefit management, will present five new studies at the Academy of Managed Care Pharmacy's (AMCP) annual meeting, April 7-10, 2010 in San Diego. Being presented on Friday, April 9 are:

Advertisement

• Adherence to chronic medication therapy associated with 90-day supplies compared to 30-day supplies. Researchers evaluated whether there is a difference in medication adherence for patients prescribed 90-day compared to 30-day supplies of their medications.
• Influenza antiviral drug utilization during flu seasons and the present H1N1 pandemic: quantity limit opportunity assessment. During the recent H1N1 pandemic, the Centers for Disease Control (CDC) recommended antiviral drugs for select populations in September 2009. Prime compared the use of influenza drugs oseltamivir (Tamiflu®), zanamivir (Relenza®), and rimantadine (Flumadine®) during this season to typical flu seasons.
• Erythropoiesis Stimulating Agents (ESA) trends and utilization management opportunity. Safety concerns associated with use of erythropoiesis stimulating agents (ESA) in cancer patients resulted in a November 2007 prescribing information black box warning. Researchers analyzed ESA claims to identify per member per month (PMPM) medical benefit and pharmacy benefit trends to determine whether ESA users may still be at increased risk.
• Oral oncology prescription abandonment association with high out-of-pocket (OOP) member expense. Increased out-of-pocket (OOP) member expense may result in some members not initiating their medication. This study evaluates the impact OOP costs have for patients taking oral oncology therapy.
• Letrozole (Femara®) medical and pharmacy integrated analysis: utilization management opportunity. Femara ® (letrozole) is a medication that can help prevent breast cancer from returning in women with hormone receptor-positive breast cancer. It has also been studied for the treatment of infertility; however, there is insufficient evidence as to its safety. This study evaluates the use of letrozole for non-FDA approved indications.

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.7 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 11 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.

SOURCE Prime Therapeutics LLC